益生菌补充对性结肠炎管理影响的研究进展
Yangyang Xu1, Jie Zhang1, Ruitao Cai1
1School of Biological Science and Technology, University of Jinan, Jinan 250024, China.
Nutrients
|December 31, 2025
概括
益生菌在治疗性结肠炎 (UC) 中表现有前途,通过恢复肠道平衡和减少炎症. 对特定益生菌菌株的进一步研究可能为这种慢性疾病提供新的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种原因不明的慢性炎症性肠病,其特征是腹痛,腹和血.
- 在UC患者中,肠道微生物群失生症越来越被认可,这表明肠道细菌在疾病发病过程中的作用.
- 目前对UC的治疗干预经常面临有效性和复发的挑战.
研究的目的:
- 审查益生菌可以缓解性结肠炎症状和调节炎症的机制.
- 探索益生菌补充剂在治疗UC中的临床应用和有效性.
- 为了解益生菌作为UC治疗策略的潜力提供见解.
主要方法:
- 审查现有的动物研究和临床试验对益生菌在UC使用.
- 对益生菌对肠道微生物群组成和功能影响的研究分析.
- 在UC的背景下检查研究研究益生菌的免疫调节作用的研究.
主要成果:
- 益生菌补充可以通过促进有益细菌和抑制病原体,恢复肠道微生态系统的平衡.
- 益生菌调节免疫反应,减少促炎细胞因子,增强抗炎细胞因子,从而减轻肠道炎症.
- 某些益生菌可以改善肠道屏障功能,减少病原体的入侵,增强肠道的透性.
结论:
- 益生菌在通过多种机制控制性结肠炎症状方面显示出显著的潜力.
- 益生菌在UC中的有效性因使用的特定菌株而异.
- 进一步的研究和益生菌的临床应用为UC治疗提供了有前途的途径.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
416
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
416
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
609
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
609
Peptic Ulcer Disease IV: Management
397
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
397
Inflammatory Bowel Disease V: Surgical Management
423
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
423
Inflammatory Bowel Disease IV: Pharmacological Management
439
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
439
Inflammatory Bowel Disease I: Ulcerative Colitis
854
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
854


